1. Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy
- Author
-
Lin JIANG, Jingbo ZHANG, Jiaqi HU, Haixiang QI, and Heng XU
- Subjects
proteolysis targeting chimeria ,lung neoplasms ,egfr ,alk ,kras ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Proteolysis targeting chimeria (PROTAC) degrades target proteins by utilizing the ubiquitin-proteasome pathway, subverting the concept of traditional small molecule inhibitors. Among the common mutation targets of non-small cell lung cancer (NSCLC), PROTAC technology has successfully achieved the effective degradation of kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK ) and other proteins in preclinical studies. PROTAC drugs with their unique event-driven advantages, are expected to overcome acquired drug resistance caused by small molecule inhibitors and show good therapeutic potential for undruggable targets, thereby providing a new strategy for the treatment of NSCLC.
- Published
- 2022
- Full Text
- View/download PDF